Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Adalimumab
Adalimumab
Routinely available
SMC (218/05)
04/12/2024
Indication
Active and progressive psoriatic arthritis
Therapeutic Area
Musculoskeletal and joint diseases
Status Description
Routinely available in line with national guidance
Formulation
-
Comments
Refer to pathway or local board guidelines for preferred formulation